Month: February 2022

SummaryThe market for the company’s vessels has improved through 2021 and activity in the fourth quarter has been significantly better than a year ago. The company’s operations have been affected by Covid-19 through restrictions and costs related to quarantine and testing. An agreement with lenders entered into in 2020 clarifies the company’s obligations to lenders until the end of 2024. One vessel was sold in the fourth quarter in accordance with the agreement. Finanstilsynet has ordered the company to carry out new impairment assessments for vessels as of 31/12/19 and 30/06/20. The company has complied with the order and the effects are shown in note 7.Havila Shipping ASA achieved an operating income before depreciation of NOK 36.4 million in Q4 2021, compared with NOK 32.8 million in Q4 2020. Total operating income was NOK 144.9 million...

Conference Call and Webcast Today at 8:30 a.m. ETU.S. FDA lifts clinical hold on IND application for COVAXIN™ (BBV152), clearing the pathway for Phase 2/3 clinical trial in support of a BLA submission Engagement with U.S. FDA to advance pediatric EUA for COVAXIN™ included submission of a real-world safety database of more than 36 million vaccinated teens along with neutralization data against Omicron Comprehensive responses regarding COVAXIN™ submitted to Health Canada for the NOD OCU400 Phase 1/2 clinical trial initiated for the treatment of inherited retinal diseases caused by NR2E3 and RHO disease genotypesMALVERN, Pa., Feb. 25, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen) (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...

Delivered 2021 results exceeding the high end of guidance Increased 2022 adjusted EBITDA guidance Provided 2023 adjusted EBITDA early outlook Increased dividend by 7%DETROIT, Feb. 25, 2022 (GLOBE NEWSWIRE) — DT Midstream, Inc. [www.dtmidstream.com] (NYSE: DTM) today reported full year 2021 net income of $307 million, or $3.16 per diluted share. Operating earnings for 2021 were $336 million, or $3.46 per diluted share, and adjusted EBITDA was $768 million. Reconciliations of operating earnings, operating EPS and adjusted EBITDA (non-GAAP measures) to reported net income are included at the end of this news release. “Our excellent 2021 results have positioned DT Midstream for continued distinctive shareholder performance,” said David Slater, President and CEO. “Our employees delivered a successful spin-off from DTE Energy, expanded...

~ Data from largest gene therapy study in hemophilia B showed sustained therapeutic effect at 18-months and statistical superiority in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy; Submissions of marketing applications on track for the first half of 2022 ~ ~ Data from first four patients in ongoing U.S. Phase I/II clinical trial in Huntington’s Disease showed AMT-130 was well tolerated, with no significant safety concerns observed ~ ~ Additional clinical data from all patients in lower dose cohort of U.S. Phase I/II study of AMT-130, including mHTT and NfL biomarkers, expected to be presented in second quarter of 2022 ~ ~ Initiated enrollment of European Phase Ib/II study of AMT-130 with first two patients dosed ~ ~ Refractory temporal lobe epilepsy and Fabry programs advancing into IND-enabling studies...

TORONTO, Feb. 25, 2022 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the year ended December 31, 2021. Management commentary “Each of Sprott’s business units performed well in 2021 and our Assets Under Management (“AUM”) finished the year at $20.4 billion, up $3.1 billion (18%) from December 31, 2020. This led to Sprott generating full year net income of $33.2 million ($1.33 per share), up 23%, or $6.2 million ($0.23 per share) from the year ended December 31, 2020. Additionally, adjusted base EBITDA1 for the year reached a record high of $64.1 million ($2.58 per share), up 45%, or $19.9 million ($0.78 per share) from the year ended December 31, 2020. The key driver of our success in 2021 was our Exchange Listed Products segment, which generated $3.1 billion...

Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year SOUTH SAN FRANCISCO, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2021. “Our confidence in efruxifermin’s (EFX’s) potential to be a best-in-class FGF21 analog for the treatment of NASH continues to grow,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “In 2021 we built on the strong results from our Phase 2a study evaluating EFX in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) by initiating two Phase...

 All amounts in U.S. dollars unless otherwise stated TORONTO, Feb. 25, 2022 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the fourth quarter and full year ended December 31, 2021. “Onex had a good year. We made progress across all our businesses and delivered solid performance,” said Gerry Schwartz, Chairman and Chief Executive Officer of Onex. “For 2022, we’re focused on continued strong execution and growing fee-generating assets under management.   With the right culture, expertise and team in place, we’re confident in our ability to successfully achieve the strategic plan we’ve laid out and continue driving long-term value for all our stakeholders.” Net Earnings and Segment ResultsFor the periods ended December 31 Three Months Ended Year Ended($ millions except per share amounts) 2021   2020   2021   2020  Net...

Net income of $18 million for the full year 2021 Net loss of $2 million in the quarter including $14 million of income statement notables $43 billion of new servicing additions in the quarter, including $32 billion in subservicing Closed reverse servicing platform acquisition from Reverse Mortgage Solutions, Inc. (“RMS”) with $14 billion in UPB with an additional $13 billion expected in the first half of 2022 Top servicing performance awards by GSEsWEST PALM BEACH, Fla., Feb. 25, 2022 (GLOBE NEWSWIRE) — Ocwen Financial Corporation (NYSE: OCN) (“Ocwen” or the “Company”), a leading non-bank mortgage servicer and originator, today announced its full year and fourth quarter 2021 results and provided an update on the Company’s key business priorities. The Company reported adjusted pre-tax income of $10 million for the fourth quarter,...

ATLANTA, Feb. 25, 2022 (GLOBE NEWSWIRE) — Gray Television, Inc. (“Gray,” “we,” “us” or “our”) (NYSE: GTN) today announced financial results for the fourth quarter ended December 31, 2021. While the quarter did not include political advertising revenue at the robust levels experienced in the fourth quarter of 2020, our total revenues of $721 million were strong for an off-year of the two-year political advertising cycle, and higher than our anticipated results due to continued improvement in economic conditions and our acquisition of the Local Media Group of Meredith Corporation on December 1, 2021, and Quincy Media on August 2, 2021. Most notably, in the fourth quarter 2021 our combined local and national broadcast advertising revenue, excluding political advertising revenue (“Total Core Revenue”) increased by 26%, and our retransmission...